Track Grifols, S.A. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Grifols, S.A. GIFLF · Stock Open Grifols, S.A. in new tab

10.45 USD
P/E
13.70
EPS
0.77
Yield
0.82%
Safety Score
77
P/B
1.16
ROE
6.93
Beta
1.20
Loading chart...
Key Metrics
Earnings dateNov. 10, 2026
P/E13.70
EPS0.77
Book Value9.13
Price to Book1.16
Debt/Equity117.24
% Insiders31.194%
Growth
Revenue Growth-0.01%
Earnings Growth0.33%
Dividend
Dividend Yield0.82%
Annual dividends0.08 USD
Ex-Div. DateJuly 1, 2026
Payout28.31%
5y avg Yield1.42%

DCF valuation

Model fair value for Grifols, S.A. (GIFLF)
Result
Sign in to run the valuation for GIFLF.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Grifols, S.A. Logo Grifols, S.A. Analysis (GIFLF)

Spain Health Care Official Website Stock

Is Grifols, S.A. a good investment? Grifols, S.A. (GIFLF) is currently trading at 10.45 USD.

In terms of valuation, the stock trades at a P/E ratio of 13.70. This relatively low multiple may signal that Grifols, S.A. is undervalued compared to historical market norms.

Earnings Schedule: Grifols, S.A. is expected to release its next earnings report on Nov. 10, 2026.

For income investors, Grifols, S.A. pays a dividend yield of 0.82%. With a payout ratio of 28%, the dividend appears sustainable.

Investor FAQ

Does Grifols, S.A. pay a dividend?

Yes, it pays an annual dividend of 0.08 USD (0.82% yield).

What asset class is Grifols, S.A.?

Grifols, S.A. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 10, 2026. The company currently has a trailing EPS of 0.77.

Company Profile

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Exchange Ticker
FRA (Germany) OZTA.F
MCE (Spain) GRF.MC
STU (Germany) OZTA.SG
ES0171996087
PNK (United States) GIFLF
Trades
Dividend Yield
0.82%
5y avg 1.42%
Annual Dividends
0.08USD
Next Ex. Div Date
July 1, 2026
Payout Ratio
28.31%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
0.09 USD
July 2, 2027 (estimated) 0.0938
▸2026
0.09 USD
July 2, 2026 0.0938
▸2025
0.18 USD
Aug. 13, 2025 0.1751
▸2021
0.44 USD
June 7, 2021 0.4416
▸2020
0.19 USD
Oct. 28, 2020 0.1909
▸2019
0.39 USD
Dec. 4, 2019 0.2214
June 11, 2019 0.1644
▸2018
0.46 USD
Dec. 4, 2018 0.2265
June 5, 2018 0.2382
▸2017
0.37 USD
Dec. 5, 2017 0.2136
June 1, 2017 0.1517
▸2016
0.34 USD
Dec. 7, 2016 0.1930
June 7, 2016 0.1479
▸2015
0.71 USD
Dec. 10, 2015 0.3828
June 8, 2015 0.3314
▸2014
0.59 USD
Dec. 4, 2014 0.3127
June 5, 2014 0.2733
▸2013
0.66 USD
June 5, 2013 0.2618
May 31, 2013 0.4000
▸2010
0.16 USD
July 1, 2010 0.1594
▸2009
0.96 USD
Dec. 18, 2009 0.2196
June 2, 2009 0.2721
May 28, 2009 0.4642
▸2008
0.26 USD
June 23, 2008 0.2561
▸2007
0.08 USD
July 2, 2007 0.0823
Upcoming Dividends
Name Payment Date Status Amount
Grifols, S.A. Jul 02, 2026 0.0938 USD
Stock Splits
Split Date Split Ratio to 1
Jan. 4, 2016 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion